胰高血糖素样肽1治疗2型糖尿病合并非酒精性脂肪性肝病的研究进展  

Research progress of glucagon-like peptide-1 treating type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease

作　　者：刘莹[1] 项莹[1] 

机构地区：[1]哈尔滨医科大学附属第二医院内分泌与代谢病科,150086

出　　处：《中国医药》2016年第8期1260-1264,共5页China Medicine

摘　　要：胰高血糖素样肽1（GLP-1）是一种肠促胰素，通过多种途径参与机体血糖稳态的调节，针对此靶点开发的药物现已广泛应用于2型糖尿病的治疗。非酒精性脂肪性肝病（NAFLD）主要与肝内脂肪过渡沉积有关，其发病率正在逐年上升，并且与2型糖尿病关系密切。本文通过讨论GLP-1作用于胰岛细胞及肝脏细胞的机制，阐述其对2型糖尿病合并NAFLD的治疗作用，并介绍目前的研究进展。Glucagon-like peptide-1 （GLP-1）is a kind of incretin which is involved in the regulation of blood glucose homeostasis through different ways. At present, GLP-1 is widely used in the treatment of type 2 diabetes mellitus（T2DM）. Nonalcoholic fatty liver disease（NAFLD） is mainly caused by the deposition of liver fat and the incidence is increasing year by year. NAFLD is closely related to T2DM. This article discussed action mechanism of GLP-1 on islet cells and hepatic cells, explored the effect on T2DM complicated with NAFLD and summarized current research progress.

关 键 词：2型糖尿病 非酒精性脂肪性肝病 胰高血糖素样肽1 肠促胰素 

分 类 号：R587.1[医药卫生—内分泌]